NexMR
AcquiredStarting off on the right molecules
- Business Model
- B2B
- Website
- nexmr.com
- Acquisition Date
- Jul 2026
About
NexMR provides benchtop NMR technology for early-stage drug discovery, offering sensitivity-enhanced NMR that accelerates experimental turnaround and enables researchers to determine hit affinities using isotope labelling. Its approach is up to 30-50-fold faster than conventional methods, is compatible with benchtop NMR equipment, and can reduce required sample concentration by 10-100-fold. NexMR was co-founded by CEO Dr. Félix Torres, who holds a PharmD and PhD in Chemistry from ETH Zürich, alongside CSO Dr. Matthias Bütikofer.
Summary
NexMR is a Biotech company.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2026
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nexmr"><img src="https://indexed.vc/api/badge/company/nexmr" alt="NexMR on Indexed.vc" width="260" height="76" /></a>